How Much Does Keytruda (pembrolizumab) Cost in the U.S. in 2025? Prices, Insurance & Savings Options
📰 Article Excerpt (Latest Update – October 23 2025) In October 2025, the cost of Keytruda (pembrolizumab) in the United States remains one of the most discussed topics in oncology pricing. As of this month, the average retail price per infusion ranges between $9,600 – $11,700, depending on dosage and healthcare facility fees. Merck’s upcoming subcutaneous version, Qlex, is expected to launch in early 2026 at a similar price level, designed to reduce hospital visit times and infusion costs. Industry analysts project combined Keytruda + Qlex sales to reach nearly $33 billion by 2026, with up to 40 percent patient adoption of the new formulation by 2027. However, after 2028—when Keytruda’s patent exclusivity ends—biosimilar competition could push treatment prices down by 15–30 percent, particularly within Medicare and private insurance plans. For U.S. patients, 2026 may bring slight out-of-pocket relief if new government price-negotiation rules take effect, while oncology clinics anticipate improved accessibility through shorter, clinic-based Qlex administration. Overall, Keytruda remains a key therapy in immuno-oncology, but cost dynamics are expected to shift significantly between 2026 and 2028.
Read More
